A 92-patient randomized trial in Taiwan tested whether 6-month health coaching improves eGFR in type 2 diabetes with early-stage CKD. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
An exploratory plasma proteomic analysis of the Phase 2b MOSAIC trial maps selonsertib activity to fibrosis, inflammation and oxidative-stress pathways in diabetic kidney disease, with PICO summary and expert commentary.
A prespecified FIGARO-DKD subgroup analysis of 325 Chinese adults with type 2 diabetes and CKD found a significant reduction in the secondary kidney outcome with finerenone but no significant cardiovascular benefit. PICO summary and expert commentary.
A small open-label RCT testing whether real-time CGM feedback added to individualized nutrition therapy improves diet and sleep in prediabetes with overweight or obesity. PICO summary and expert commentary.
A 2×2 cluster RCT in 284 adults with type 2 diabetes and overweight or obesity testing whether nudge-based dietary education and tableware lower HbA1c. PICO summary and expert commentary.
A small randomized trial of CGM-guided insulin titration in cardiac surgery patients with type 2 diabetes and prediabetes missed its primary time-in-range endpoint but improved several secondary glucose metrics. PICO summary and expert commentary.
A small single-site quasi-experimental study tested whether an Information-Motivation-Behavioral Skills education programme raises medication adherence in older adults with type 2 diabetes. PICO summary and expert commentary.
An unblinded randomized trial testing whether adding the Vitadio self-management app to standard care improves HbA1c in type 2 diabetes. PICO summary and expert commentary.
A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.